Betamethasone-21-acetate

Amiard, G., Torelli.V. and Cerede, J. U.S. Patent 3,104,246 September 17, 1963 assigned to Roussel-UCLAF, SA, France 

Rausser, R. and Oliveto, E.P. U.S. Patent 3,164,618 January 5, 1965 assigned to Sobering Corporation 

Chemical Name 9-fluoro-11/3,17,21-trihydroxy-16/3-methylpregna-1,4-diene-3,20-dione-21-acetate 

21 -Dihydroxy-16 methyl-4,9(11 )-pregnadiene-3,20-dlone 21 Acetate N-Bromosuccinimide Perchloric Acid 

The synthesis is long and complex. For brevity, only the last steps are given here. Refer to the patents cited below for full details. 

---

Betamethasone acetate is converted to betamethasone by means of hydrochloric acid in a methanol-chloroform-water mixture as described in U.S. Patent 3,164,618. 

Betamethasone benzoate Betamethasone valerate Betamethasone acetate Betamethasone... 

Bromo pyruvaldoxime Methotrexate N-Bromosuccinimide Betamethasone acetate Bromocriptine Medrogestone 2-Bromothiophene Thihexinol... 

Betamethasone sodium phosphate and acetate - Betamethasone sodium phosphate provides prompt activity, while betamethasone acetate affords... 

Betamethasone is hardly ever used orally. It has a long duration of activity and can therefore also be used for alternate-day therapy. The parenteral formulation is also the sodium phosphate salt which when given IV or IM has a rapid onset of action. There are many similarities with dexamethasone such as their metabolic pathways and the indications for which both steroids are used, like the prevention of neonatal RDS and reduction of raised intracranial pressure. Combinations of betamethasone acetate and sodium phosphate have, when used for intra-articular and intra-lesional injections, the dual advantage of a rapid onset of action together with the long duration of action of a depot preparation. 

Glucocorticoids betamethasone acetate betamethasone sodium phosphate cortisone acetate dexamethasone dexamethasone sodium phosphate hydrocortisone... 

The limited penetration of topical corticosteroids can be overcome in certain clinical circumstances by the intralesional injection of relatively insoluble corticosteroids, eg, triamcinolone acetonide, triamcinolone diacetate, triamcinolone hexacetonide, and betamethasone acetate-phosphate. When these agents are injected into the lesion, measurable amounts remain in place and are gradually released for 3-4 weeks. This form of therapy is often effective for the lesions listed in Table 61-2 that are generally unresponsive to topical corticosteroids. The dosage of the triamcinolone salts should be limited to 1 mg per treatment site, ie, 0.1 mL of 10 mg/mL suspension, to decrease the incidence of local atrophy (see below). 

Betamethasone Acetate 452.5 Fluocinolone Acetonide 474.6 Fluocortolone Hexanoate... 

Betaioe metoprolol. betameprodine meprodine. betamethadol dimepheptanol. betamethasone [ban. inn, jan, usan] (betamethasone acetate [jan, usan] betamethasone benzoate [ban, usan] ... 

---